The BIA has published a new guide to the Patent Box, developed by members of the Finance and Tax Advisory Committee and to be officially launched at the BIA Committee Summit on 22 February. Here, FTI Consulting’s Richard Turner takes a look at the impact the Patent Box has had on the UK life sciences sector.
This week we are gearing up for our 2018 Committee Summit taking place on Thursday, kindly hosted by Simmons and Simmons. The event will see around 180 expert BIA members gather for all eight of the BIA’s advisory committees coming together. In addition, this year we are running a plenary session on the implications of the Nagoya protocol for our sector.
The BIA’s Charity of the Year for 2017 was Alzheimer’s Research UK, and we are proud to have supported them throughout the year. In this blog, we take a quick look back at some of the highlights of our partnership.
Thank you to all our members who joined our Brexit lead event last week. It was great to be able to share perspectives on what is a fast moving key issue. I was pleased that members confirmed that we should stay our course on the Brexit priorities agreed last year, which we will keep stressing to the UK government, and with our European partner associations to the EU-27.
Last week saw the launch event for the China Biotech Special Interest Group. We had an excellent turn out at the China-Britain Business Council offices in Victoria, with people coming to hear BIA members talk about their different experiences in China.
The Biomedical Catalyst (BMC), a unique partnership between Innovate UK and the MRC, was established in 2012 as part of a wider package of measures to support the life sciences sector.
By Dr Michael Kipping, Innovation Lead, Biomedical Catalyst, Innovate UK.
Last week we released our latest quarterly report ‘Influencing and shaping our sector, BIA update October 2017 – January 2018’. These quarterly updates give an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry.
The year started with a bang with the BIA launching its Best Practice Communications guide, the annual finance report and three events on the Gala Dinner day. The turn of the year saw a resurgence in deal-making and fundraising. January ended with major global M&A transactions with large players looking to boost pipelines with Biotech acquisitions: Celgene’s US$9bn acquisition of Juno Therapeutics and Sanofi's US$11.6bn for haemophilia drugmaker Bioverativ.
The BIA’s annual report on sector financing shows the UK has the strongest clinical and preclinical pipeline in Europe.
Do download ‘Pipeline Progressing: the UK’s global bioscience cluster in 2017’, produced with our data partner Informa Pharma Intelligence.
On Thursday we released our joint report with the Medicines Discovery Catapult ‘State of the Discovery Nation 2018’. Launched by Sir Mark Walport at Alderley Park, the report is based on surveys and over 100 in-depth interviews with senior executives of UK drug discovery companies and shows that global R&D productivity is under unprecedented pressure. The BIA, along with the Medicines Discovery Catapult, is committed to working with others to create long-term solutions to these issues, which will drive productivity and further success in the important years ahead.